HHS Ordering 20 Million Doses Of Bavarian Nordic's Imvamune

Boggs, Jennifer
April 2007
BioWorld Today;4/17/2007, Vol. 18 Issue 74, p1
The article reports on the plan of the U.S. Department of Health and Human Services to buy 20 million doses of the Imvamune vaccine from Bavarian Nordic A/S. It might be the first contract award under the U.S. RFP-3, a request for proposals for modified vaccinia ankara (MVA)-based vaccine for smallpox. Bavarian Nordic says the value of the contract might reach $500 million. Imvamune is based on a live, nonreplicating strain of the MVA virus.


Related Articles

  • Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion. Sheridan, Cormac // BioWorld International;6/6/2007, Vol. 12 Issue 23, p1 

    The article reports on the contract won by Bavarian Nordic A/S to supply a stockpile of next-generation safe smallpox vaccines to the U.S. Department of Health and Human Services. The pharmaceutical company is expected to earn a total of $1.6 billion from the contract. The vaccine produced by...

  • HHS Ordering 20 Million Doses Of Imvamune.  // Bioworld Week;4/23/2007, Vol. 15 Issue 17, p3 

    The article reports on the planned acquisition of 20 million doses of Imvamune, a third-generation smallpox vaccine from Kvisgard, Denmark-based Bavarian Nordic AS by the U.S. Department of Health and Human Services, for its strategic national stockpile in Kvisgard, Denmark. The move which is...

  • Danish Biopharma Company Secures $500-Million U.S. Contract. Scott, Alex // Chemical Week;6/20/2007, Vol. 169 Issue 21, p31 

    The article highlights the announcement of the U.S. Department of Health and Human Services (HHS) that it had agreed to contract out the manufacture of 20 million doses of smallpox vaccine to biopharmaceutical company Bavarian Nordic for $500 million. The value of the groundbreaking deal could...

  • Bavarian Nordic: HHS contract boosts smallpox vaccine franchise.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p23 

    The article reports on the U.S. government supply contract earned by Bavarian Nordic for its smallpox vaccine Imvamune. It is stated that the U.S. department of Health and Human Services has informed Bavarian Nordic of its plan to purchase 20 million doses of Imvamune under the BioShield...

  • Acambis and Bavarian Nordic Vie for Smallpox Vaccine Contract. Bush, Laura // Pharmaceutical Technology;Sep2005, Vol. 29 Issue 9, p24 

    Reports on the issuance of a request for proposals by the U.S. Department of Health and Human Services to acquire the doses of modified vaccinia Ankara (MVA) vaccine, a highly attenuated live smallpox vaccine. Competition between pharmaceutical firms Acambis PLC and Bavarian Nordic AS for the...

  • GOVERNMENT OF CANADA PROCURES IMVAMUNE SMALLPOX VACCINE.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p6 

    The article reports on the contract awarded by Public Works and Government Services Canada to Bavarian Nordic in January 2009 for the delivery of Imvamune, a Modified Vaccinia Ankara (MVA)-based, third generation smallpox vaccine. As stated, the procurement will be used by the Canadian...

  • OTHER NEWS TO NOTE.  // BioWorld International;11/26/2008, Vol. 13 Issue 48, p2 

    This section offers news briefs on the biotechnology industries. Asterand plc has completed a placement of 4.3 million shares at 15 pence each. Bavarian Nordic A/S received a $25 million milestone payment from the U.S. government by submitting safety data from a Phase II trial of smallpox...

  • Production of smallpox vaccine approved.  // Pharmaceutical Technology Europe;Nov2006, Vol. 18 Issue 11, p14 

    The article reports on the approval of the production facility of Bavarian Nordic AS in Kvistgard, Denmark by the Danish Medicines Agency. After the authorization, the company could start to operate as a large-scale commercial production of smallpox vaccine. On the other hand, the company...

  • Bavarian Nordic Rises On First Vaccine Approval. Sheridan, Cormac // BioWorld International;8/14/2013, Vol. 18 Issue 33, p5 

    The article reports on the 6.6% increase in pharmaceutical company Bavarian Nordic A/S shares. It notes that this increase resulted from European Commission's approval of Bavarian Nordic's third-generation smallpox vaccine Imnavex which is based on a modified vaccinia Ankara (MVA) vector. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics